What is the difference between Eloralintide and Pramlintide?

Eloralintide: Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying Pramlintide: Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Is Pramlintide FDA approved?

Pramlintide is FDA approved (FDA status current as of 2005-03-16). This regulatory status is provided for research and educational context only.

How is Eloralintide administered in research settings?

In research settings, Eloralintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

How is Pramlintide administered in research settings?

In research settings, Pramlintide is typically administered via the subcutaneous route. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›Eloralintide vs Pramlintide

Peptide Comparison

Eloralintide vs Pramlintide

Both are Metabolic peptides.

Eloralintide

LY3841136

Fat LossUnder clinical reviewResearch Only

Half-life: Not published

1 providers listed

Full Eloralintide profile →

Pramlintide

Symlin

Fat LossFDA ApprovedPrescription

Half-life: ~48 minutes

No providers listed yet

Full Pramlintide profile →

Bottom line

Pramlintide is FDA-approved, while Eloralintide is investigational — the clearest structural difference between them.

Quick Verdict

Eloralintide

Half-life

Not published

Pramlintide

Half-life

~48 minutes

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	Eloralintide
Further along in FDA review	Pramlintide
More provider options (1 vs 0)	Eloralintide

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

Eloralintide

Pramlintide

Mechanism Family

Metabolic

Half-life

Not published

~48 minutes

FDA Status

Under clinical review

approved

Admin Routes

subcutaneous

Availability

Research Only

Prescription

Providers

1 listed

None listed

FDA Update

Under clinical review

Mar 2005

Avail. Notes

Selective amylin receptor agonist by Eli Lilly. Phase 2 complete (The Lancet, Nov 2025; n=263, 48 weeks). Phase 3 ENLIGHTEN programme opened Dec 2025-Feb 2026 across obesity (NCT07321886), type 2 diabetes (NCT07282600), obstructive sleep apnoea (NCT07369011) and knee osteoarthritis (NCT07353931). Not FDA-approved; no application on file; lead primary completion 2028.

FDA-approved amylin analog. Brand: Symlin (NDA 021332, Mar 2005). Adjunct to insulin therapy in T1D and T2D. Prescription only. Subcutaneous injection.

Research Evidence

Eloralintide

Meta-analysis · 4 key studies · most recent 2026

Pramlintide

RCT · 3 key studies · most recent 2026

Research Citations

Eloralintide

Meta-analysis2026 · Endocrinol Diabetes Metab

Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…

RCT2026 · Diabetes Obes Metab

Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of con…

RCT2025 · Lancet

Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase 2, multicentr…

RCT2025 · Mol Metab

Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to cli…

Pramlintide

RCT2009 · Obesity

Pramlintide combined with metreleptin in obesity: sustained reductions in weight, metabolic markers, and lept…

RCT2007 · American Journal of Physiology: Endocrinology and Metabolism

Pramlintide reduced 24-h caloric intake and increased satiety in obese subjects: a randomized, double-blind,…

In vitro2026 · J Pharm Biomed Anal

In vitro metabolic profiling of weight-loss-inducing amylin receptor agonists in the context of preventive do…

About Eloralintide

Selective long-acting amylin receptor agonist; preferentially activates AMY1R over the calcitonin receptor to prolong satiety and slow gastric emptying

Research Areas

appetite suppressionweight losssatiety signaling

About Pramlintide

Synthetic amylin analogue; activates amylin receptors in hypothalamus; slows gastric emptying, suppresses glucagon, enhances satiety

Research Areas

appetite suppressionpostprandial glucose controlweight lossgastric emptying delay

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

Eloralintide

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

HbA1cFasting glucoseTSHCalcitoninLipaseeGFRALT/AST

No amylin-specific monitoring protocol is established for eloralintide, which remains investigational and is available only through clinical trials. Trial programmes track a baseline metabolic panel covering glycaemic markers, renal and hepatic function, and lipase. Calcitonin and TSH are carried over from incretin-class convention rather than from any eloralintide-specific signal, as the compound is designed for reduced calcitonin receptor activity.

Pramlintide

Reported (Unverified — Pending Clinical Review)

hypoglycemia unawarenessgastroparesis

No established clinical contraindications

Suggested Monitoring

Under clinical review

Being verified by our medical team before we display monitoring guidance for this peptide.

Find Providers

Where to source these peptides

Providers offering

Eloralintide

1 listed

Browse directory →

Providers offering

Pramlintide

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Metabolic Comparisons

Browse all peptides →

Educational research tools — not medical advice.